
Vertex Pharmaceuticals, Danaher, and United Therapeutics are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies focused on developing, manufacturing, or commercializing biologically based medical products—such as drugs, gene therapies, vaccines, and diagnostics—or the enabling technologies used to create them. For investors they often offer high growth potential but also elevated risk and volatility, since valuations depend heavily on long R&D timelines, binary clinical-trial and regulatory outcomes, and patent or partnership milestones. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read Our Latest Research Report on DHR
United Therapeutics (UTHR)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read Our Latest Research Report on UTHR
Featured Stories
- MarketBeat’s Top Five Stocks to Own in April 2026
- 3 Utility Stocks With Strong Dividends and Room to Run Higher
- 3 Energy Stocks to Buy as AI Power Demand Surges—and 2 to Avoid
- LendingClub: A Digital Bank Growing Again Like a Fintech
- 3 Edge AI Stocks to Watch as the Next Wave of AI Demand Builds
- Why Meta’s “Bellwether” Legal Loss Could Open up a Can of Worms
